Bremelanotide (PT-141)

Bremelanotide (PT-141) is a synthesized, seven-amino-acid cyclic peptide whose chemical structure is analogous to $\alpha$-melanocyte-stimulating hormone ($\alpha$-MSH). It functions as a ligand that activates melanocortin receptors, showing preferential activity at the MC4R and MC3R subtypes. The research on PT-141 is concentrated on its ability to modify the melanocortin pathway, influence sexual conduct, and alter central nervous system (CNS) signaling. Crucially, compared to its predecessors in the melanocortin peptide class, PT-141 exhibits minimal affinity for the MC1R receptor, the subtype that controls skin pigmentation. This focused receptor specificity makes PT-141 an outstanding experimental agent for investigating central melanocortin mechanisms without the confounding factor of altering skin color.

Summary of the PT-141 Peptide

PT-141 was engineered by modifying the $\alpha$-MSH derivative, Melanotan II, specifically to improve its potency and targeting toward the central melanocortin receptors associated with appetite control and sexual function. Experimental data indicates that PT-141 affects neuronal activity in the brain's hypothalamus, thus regulating sexual arousal, behavior, and the desire for food. Investigations have been conducted in preclinical models to explore the effects of PT-141 on neuroendocrine signaling, metabolic stability, and sexual dysfunction, underscoring its importance as a research tool for dissecting the roles of central melanocortin pathways in the regulation of behavioral and neural systems.

PT-141 Peptide Studies

Melanocortin System and Sexual Behavior

Studies in animal models confirm that PT-141 stimulates the MC4R and MC3R receptors within the hypothalamus, effectively inducing sexual motivation and copulatory activity in both male and female subjects. Unlike medications such as PDE5 inhibitors, which improve function peripherally (e.g., via vascular changes), PT-141 operates by targeting central neural pathways. This makes it an invaluable research agent for dissecting the neuroendocrine control of sexual function.

Energy Balance and Neuroendocrine Function

The melanocortin signaling cascade is vital for maintaining appetite regulation and energy homeostasis. Research using PT-141 has explored its capacity to reduce food consumption and influence weight management in various rodent models, emphasizing its relevance to studies of metabolic and neuroendocrine physiology.

CNS Pharmacokinetics and Safety Profile

PT-141 is of scientific interest for neuroendocrine and metabolic research due to its efficient crossing of the blood–brain barrier and its specificity for targeted receptors. Initial pharmacological evaluations suggest that the compound is generally safe when administered via controlled experimental methods, such as subcutaneous or intranasal injection.

Broader Research Applications

Further exploratory research has examined the compound’s utility in areas including neuroinflammatory modulation, protection against ischemia, and behavioral studies. These diverse findings establish PT-141 as a multifaceted experimental tool for advancing research into the central nervous system mechanisms governed by the melanocortin receptor family.

Mechanism of Sexual Arousal

PT-141 is a specialized agonist peptide known to activate the MC4R receptor, which is instrumental in governing sexual behavior and arousal via pathways within the central nervous system. Experimental research in animal subjects has repeatedly shown that stimulating the MC4R receptor enhances sexual desire and performance in both genders. In contrast to vascular-acting drugs like sildenafil (Viagra), PT-141 achieves its effect via a unique neurochemical mechanism, specifically targeting the central arousal centers. This difference makes it a promising compound for investigating and potentially treating sexual arousal deficits in men and women that are rooted in neurological causes rather than blood flow issues. Clinical research conducted on men experiencing erectile dysfunction (ED) who had failed sildenafil treatment reported that approximately one-third achieved successful sexual activity following the administration of PT-141 intranasally. The data also confirmed a dose-response relationship, supporting the compound's clinical effect in specific cases. These observations indicate that PT-141 can provide valuable insight into the treatment of ED associated with CNS factors and may contribute to understanding the neurobiological basis of reduced libido.

PT-141 in Hemorrhagic Shock

In 2009, a minor modification to the structure of PT-141 was developed to investigate its therapeutic potential for hemorrhagic shock. Due to PT-141's dual function as an agonist at both MC4R and MC1R receptors, it has been shown to protect tissues from damage caused by lack of oxygen (ischemia) during conditions of severe blood volume loss (hypovolemic shock). When administered intravenously, PT-141 demonstrated no significant adverse effects. This refined compound, known as PL-6983, progressed successfully into phase IIb clinical trials, where it showed promising protective effects with a favorable toxicity profile.

Application in Infectious Disease Models

Experimental studies using rat models of fungal infection revealed that the stimulation of the MC1R receptor by PT-141 can induce marked anti-inflammatory and anti-fungal effects. This is a highly significant finding, as current anti-fungal agents are limited by their restricted mechanisms of action and frequently cause severe, dose-limiting side effects. PT-141’s distinct receptor-mediated activity positions it as a potential alternative therapeutic option for fungal infections, which is especially relevant for immunocompromised patients, where minimizing both inflammation and infection-related mortality is of paramount importance.

Article Author

This literature review was edited, compiled, and prepared by Dr. Roger T. Dorr, Ph.D., an esteemed melanoma specialist and pharmacologist globally recognized for his pioneering studies on melanocortin receptor agonists, including his involvement in the creation of PT-141 (Bremelanotide). Dr. Dorr’s pivotal work at the University of Arizona has greatly enhanced the scientific comprehension of the melanocortin system and its roles in sexual function, energy balance, and skin pigmentation. Through his decades of research, Dr. Dorr has been central to the advancement of synthetic $\alpha$-MSH analogs and the discovery of their wide-ranging therapeutic potential in neurobiological, endocrine, and dermatological applications.

Scientific Journal Author

Dr. Roger T. Dorr has authored and co-authored numerous influential papers on melanocortin receptor signaling and peptide analog pharmacology. Working alongside notable collaborators such as M.E. Hadley, J.E.S. Wikberg, L.H. van der Ploeg, and F. Giuliano, he has contributed significantly to detailing the distinct functions and regulatory roles of the melanocortin receptor subtypes (MC1R–MC5R) in neuroendocrine activity, metabolism, and sexual behavior. The collective research from these individuals has created the foundation for modern knowledge of central melanocortin mechanisms and their relevance to conditions like metabolic imbalance, neural protection, and sexual dysfunction. This acknowledgment is solely intended to credit the scholarly and experimental contributions of Dr. Dorr and his colleagues. It should not be taken as a promotional statement, endorsement, or affiliation. Montreal Peptides Canada maintains no professional, institutional, or financial association with Dr. Dorr or any of the researchers mentioned.

Reference Citations

Dorr RT, et al. Melanocortin receptor agonists and sexual function: discovery of PT-141. Ann N Y Acad Sci. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851312/

Shadiack AM, et al. Melanocortin receptor agonists in sexual behavior research. Brain Res. 2007;1124(1):166–175. https://pubmed.ncbi.nlm.nih.gov/17118440/

Hadley ME, et al. Discovery and development of melanocortin receptor ligands. Ann N Y Acad Sci. 2006;994:1-15. https://pubmed.ncbi.nlm.nih.gov/12851309/

King SH, et al. PT-141: novel melanocortin analog in sexual arousal studies. J Sex Med. 2008;5(8):1939-1948. https://pubmed.ncbi.nlm.nih.gov/18624943/

Giuliano F, et al. Central melanocortin pathways and erectile function. Int J Impot Res. 2007;19(1):17–23. https://pubmed.ncbi.nlm.nih.gov/17043692/

Clayton AH, et al. Bremelanotide in female sexual dysfunction studies. J Sex Med. 2016;13(5):696-706. https://pubmed.ncbi.nlm.nih.gov/27045212/

Wessells H, et al. Central melanocortin modulation of sexual function in humans. J Urol. 2000;164(3 Pt 1):738-743. https://pubmed.ncbi.nlm.nih.gov/10953129/

van der Ploeg LH, et al. Melanocortin receptors and obesity research. Endocr Rev. 2002;23(6):728-743. https://pubmed.ncbi.nlm.nih.gov/12466191/

Kask A, et al. Melanocortins in the brain: from pigmentation to appetite. Eur J Pharmacol. 1999;375(1-3):1–12. https://pubmed.ncbi.nlm.nih.gov/10443489/

Wikberg JES, et al. Five subtypes of melanocortin receptors in energy homeostasis.33 Peptides. 1999;20(4):401-410. https://pubmed.ncbi.nlm.nih.gov/10328292/